The Japanese Pharmaceutical Industry Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of The Japanese Pharmaceutical Industry book. This book definitely worth reading, it is an incredibly well-written.
The Japanese Pharmaceutical Industry by Lacy Glenn Thomas Pdf
Almost 90 per cent of new drugs are unavailable in Japan. This book presents an analysis of the nature, causes and consequences of this problem, contrasting the Japanese situation with the drug lag experienced in the US. The last chapters look at the various remedies available.
The Japanese Pharmaceutical Industry by Maki Umemura Pdf
This book explores why Japan, despite being a world leader in many high technology industries such as automobiles and consumer electronics, is only a minor player in the global pharmaceutical industry. Japan provides a huge market for pharmaceuticals as the second largest consumer of prescription drugs after the United States, and is a massive importer of prescription drugs, relying on discoveries made elsewhere. This book charts the development of the industry, from the devastation resulting from the Second World War to its performance in the present day. Focusing in particular on antibiotics and anticancer drugs, the book analyses factors that have prevented Japan from leading the rapid advances in science and technology that have occurred globally over recent decades. Looking at the pharmaceutical industry, the book argues that the Japanese government’s research and development policies were not sufficiently incentivising. It also shows how the nature of capitalism in Japan - which featured close relations between government and industry as well as between and within firms - was appropriate for nurturing industrial development in the immediate post-war decades, but became much less effective in later years.
Competition Law and Policy in the Japanese Pharmaceutical Sector by Akira Negishi,Masako Wakui,Naoko Mariyama Pdf
This is the first book published that focuses on competition law and policy in the Japanese pharmaceutical sector. It consists of chapters written and edited by academics who research the industry from various perspectives, including economics, competition law, pharmaceutical regulations, and intellectual property law. Competition policies involving pharmaceutical products attract attention from academics and policymakers worldwide. The pharmaceutical industry is regulated by drug laws that vary from country to country and are affected by differing practices and industrial structures. The book begins by examining drug regulations and trade practices in the industry that are peculiar to Japan and its healthcare system. It then presents the Japanese Antimonopoly Act and cases involving it, and discussions of current competition law issues in the Japanese pharmaceutical industry. The book also discusses innovation and intellectual property and economic analyses of pharmaceutical regulations and drug discovery. The chapters include comparative studies on Japanese regulations vs. those in the European Union and the United States. Japan is one of the biggest pharmaceutical markets in the world. With this in mind, the book provides “one-stop shopping” for anyone interested in pharmaceutical regulations in the country. Covering the basics but extending to in-depth explorations of complex problems, this book appeals not only to students and academics, pharmaceutical companies and regulators, but also to those dealing with real-world policy issues that encompass competition policy, intellectual property, and pharmaceutical regulation. Chapter 11 is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com
英文日本の医薬品産業 by Society of Japanese Pharmacopoeia Pdf
This book presents an analysis of the current trends and problems in the Japanese pharmaceutical industry, and attempts to find the key to future trends that will enhance the industry. With Japan being the world's second largest drugs market, the pharmaceutical industry is a key sector of the economy. The sector is, unlike the rest of the world, dominated by local companies, and the impact of major Western pharmaceutical companies has until recently been limited by the peculiar history and nature of Japanese medicine. Yet the globalisation of business is now affecting this sector, and the domestic companies are changing rapidly in order to compete more effectively, both at home and abroad, and to develop new medicines.
They Do Well Who Do Good is a collection of articles written from 2000 to 2010 that document the changes in the Japan health care system and pharma industry. Changes considered impossible in the past became routine. As the decade ended, optimists and game changers leave the pessimists and status quo keepers behind. An attractive health care system evolved to care for an aging population with chronic diseases versus a young population with acute diseases. Japan wants the best health care the world has to offer, but choices must be made because resources to pay the bill are limited. In the beginning of the decade, you could compare Japanese pharma companies to a convoy of ships. Some big, some small, some fast, some slow, but all moved together. Ten years later, the convoy analogy was no longer useful. Some went abroad, others stayed home. Some divested noncore businesses; others did not. Some merged; others choose to go alone. Some changed their business models and cultures. Other rejected change and held on to their past. They Do Well Who Do Good is an insiders perspective on what it takes to succeed in Japans pharma market.
It's Worth Doing is a must read for anyone engaged in cross-border dealings with Japan in the pharmaceutical industry. This book offers a wealth of insight that you will find invaluable whether you are a veteran Japan hand or new to the nation, whether you are a senior executive or a newly hired medical representative. P. Reed Maurer shares his decades of experience and expertise through brilliantly penned colums that are always interesting, frequently funny, and sometimes--as in the title piece--gripping. In succinct and thoroughly enjoyable prose, Maurer imparts the esence of what you will need to know to succeed in Japan. The columns collected in this volume provide a sweeping historical perspective on Japan's pharmaceutical industry and an inside view of how companies in that industry compete. They furnish practical hints about how to manage and motivate people effectively at pharmaceutical operations in Japan and how to build a strong corporate image there. Maurer exposes myths and misunderstandings about doing business in Japan, refuting them with an objective clarity that is a joy to read. It's Worth Doing is even more, however, than a treasure trove of information and insight. True to its title, the book is a compelling reminder of why you are in the pharmaceutical business. Rob Schrull President Global Business Leaders Association
Institute of Medicine,Committee on Technological Innovation in Medicine
Author : Institute of Medicine,Committee on Technological Innovation in Medicine Publisher : National Academies Press Page : 225 pages File Size : 45,7 Mb Release : 1991-02-01 Category : Medical ISBN : 9780309044912
The Changing Economics of Medical Technology by Institute of Medicine,Committee on Technological Innovation in Medicine Pdf
Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.
This book provides a broad overview of Japan's health-care industry as a context for its true purpose. That purpose is to describe the historical development over a half century from the 1960s of an international voluntary organization of pharmaceutical and service-company executives comprising both foreign and Japanese members. Known as Pharma Delegates, they gather regularly for forums and fellowship on an informal basis, while also attracting high-level speakers to their monthly luncheons and annual seminars. The book is not about the pharmaceutical industry itself. Rather, it is about the people who make the industry successful through mutual self-help, where even competitors smile at each other.
Author : L. G. Thomas Publisher : American Enterprise Institute Press Page : 120 pages File Size : 47,9 Mb Release : 1998-01-01 Category : Business & Economics ISBN : 0844740489
Japan has raised its nontariff barriers against foreign pharmaceutical firms over the past decade, to the detriment of both the international innovation of new medicines and the health of the Japanese people. This work contains documentation of Japanese exclusion.
This book provides a broad overview of Japans health-care industry as a context for its true purpose. That purpose is to describe the historical development over a half century from the 1960s of an international voluntary organization of pharmaceutical and service-company executives comprising both foreign and Japanese members. Known as Pharma Delegates, they gather regularly for forums and fellowship on an informal basis, while also attracting high-level speakers to their monthly luncheons and annual seminars. The book is not about the pharmaceutical industry itself. Rather, it is about the people who make the industry successful through mutual self-help, where even competitors smile at each other.
Innovation in the Pharmaceutical Industry by Takuji Hara Pdf
"Addressing a number of practical implications for the promotion of the pharmaceutical industry, this book will be of enormous interest to students, researchers and academics specializing in science and technology studies, and the management of technology and innovation. Practitioners, managers, and policy planners within the pharmaceutical industry will also deem this book invaluable."--BOOK JACKET.
Japanese Multinationals in Europe by Ken-ichi Ando Pdf
'Ando's well-researched comparison of Japanese automobile and pharmaceutical investment in Europe not only provides a compelling demonstration of the strategic and organizational diversity of contemporary Japanese multinationals, but illustrates the challenges faced by all multinationals by the complex and multi-faceted process of European integration.' - Geoffrey Jones, Harvard Business School, US This book explores the regional strategy and management of Japanese MNEs in Europe. Ken-ichi Ando investigates, using case studies of the auto and pharmaceutical industries, how these companies can, and do, overcome the inherent difficulties and opportunities of trading in Europe, including the problems posed by cultural differences and geography, alongside the opportunities of expanding markets. While these companies are global players, they must increasingly be aware of, and evolve in response to, European economic integration. The strategy setting and management are influenced by company- and industry-specific factors, and some common features can be found. The locational and entry strategies are based both on the multinationals' own resources and capability, and on the changing locational conditions, while pan-European management is conducted to achieve the benefits of 'multinationality' at the regional level. The mutual relationships between the location of subsidiaries, the entry mode, and the pan-European operation are clearly shown from the detailed analysis at the company level. The impacts and limits of the EU on multinationals are also confirmed in the book, and the importance of national characteristics is suggested. Scholars and graduate students studying international business and economics, as well as European integration will find this book of great interest.
